ClinicalTrials.gg
Active, not recruitingNCT06937749Updated Oct 20, 2026

A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

A Phase 2 interventional study of Placebo and IBI362 in Metabolic Dysfunction-associated Steatohepatitis (MASH), sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 2, Interventional, and Treatment

Updated Oct 20, 2026Now Active, not recruitingStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
181
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies in Fatty Liver with a site in China — 30 open to participants now, 34 under way, 2 of them phase 3. Fatty Liver · China.

Enrollment
7th of 37
181 · median 90
Started
2025
with 11 others
Phase 2
8 of 63
5 open now
Primary completion
2026-09
later than 10 of 33 live
Registered
43rd of 63
by date

Among the 63 studies in Fatty Liver with a site in China, this one is the 7th largest by enrollment of the 37 interventional ones that give a count, is one of 12 that started in 2025, is one of 8 in phase 2, reaches primary completion later than 10 of the 33 other live ones, and was the 43rd registered.

Fatty Liver

663 studies on the registry are indexed under Fatty Liver; 185 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

30 of the 63 studies in Fatty Liver with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 117 Fatty Liver studies recruiting now, 35 (30%) set no upper age limit and 63 (54%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Fatty Liver with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating the efficacy and safety of IBI362 in MASH subjects. Subjects will be randomly assigned to IBI362 low-dose, high-dose and placebo groups. The entire trial cycle includes a 8-week screening period, a 60-week double-blind treatment period, and a 4-week follow-up period.

03

Conditions studied

  • Metabolic Dysfunction-associated Steatohepatitis (MASH)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be willing to participate in the study and provide written .
  • Male or female, age 18 years or older at the time of signing informed consent
  • (BMI) ≥25 kg/m²
  • Diagnosis of Metabolic dysfunction-associated steatohepatitis (MASH) (Non-alcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS) ≥ 4, with at least 1 point in steatosis, inflammation and ballooning each) and fibrosis stage F2 or F3 proven by a conducted during the screening period or by a historical biopsy conducted within the last 3 months prior to screening

Exclusion criteria

Exclusion Criteria:

  1. Subjects who the investigator thinks may be allergic to the components in the study drug or similar drugs
  2. >10%
  3. History or current other forms of chronic liver disease other than MASH
  4. Patients with positive surface antigen (HBsAg). Patients with positive HBcAb will be eligible only when HBV DNA test negative at screening
  5. patients with antibody positive.
  6. Patients with antibody positive or syphilis specific antibodies positive (patients with non-specific antibody turned negative will be eligible)
  7. Model for End-stage Liver Disease(MELD) >12 or Child-Turcotte-Pugh(CTP) >6
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
181 participants (actual)

Study arms

  • Experimental
    IBI362 Low Dose

    Dose level 1,SC,once a week for 4 weeks; Dose level 2,SC,once a week for 4 weeks; Dose level 3,SC,once a week for 52 weeks

    Drug: IBI362

  • Experimental
    IBI362 High Dose

    Dose level 1,SC,once a week for 4 weeks; Dose level 2,SC,once a week for 4 weeks; Dose level 3,SC,once a week for for 4 weeks; Dose level 4,SC,once a week for 48 weeks

    Drug: IBI362

  • Placebo comparator
    Placebo

    Placebo,SC,once a week for 60 weeks

    Drug: Placebo

Interventions

  • DrugPlacebo

    Placebo administered subcutaneously (SC) once a week.

  • DrugIBI362

    IBI362 administered subcutaneously (SC) once a week.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With MASH resolution With no Worsening of Fibrosis on Liver Histology

    Time frame: Baseline, Week 60

Secondary outcomes

  1. Percentage of Participants With ≥1 Point Decrease in Fibrosis Stage With No Worsening of MASH on Liver Histology

    Time frame: Baseline, Week 60

  2. Percentage of Participants With MASH improvement With no Worsening of Fibrosis on Liver Histology

    Time frame: Baseline, Week 60

  3. Percentage of Participants With MASH improvement With ≥1 Point Decrease in Fibrosis Stage on Liver Histology

    Time frame: Baseline, Week 60

  4. Percentage of Participants With MASH resolution With ≥1 Point Decrease in Fibrosis Stage on Liver Histology

    Time frame: Baseline, Week 60

  5. Percentage of Participants With ≥1 Point Decrease in Fibrosis Stage on Liver Histology

    Time frame: Baseline, Week 60

  6. Mean Absolute Change and Percentage Change From Baseline in Liver Fat Content by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)

    Time frame: Baseline, Week 4, Week 12, Week 36, Week 60

  7. Percentage of participants with at least 30%, 50% and 70% relative reduction in Liver Fat Content by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) From Baseline

    Time frame: Baseline, Week 4, Week 12, Week 36, Week 60

  8. Mean Absolute Change and Percentage change From Baseline in aspartate aminotransferase[U/L]

    Time frame: Baseline, Week 36, Week 60

  9. Mean Absolute Change and Percentage change From Baseline in alanine aminotransferase[U/L]

    Time frame: Baseline, Week 36, Week 60

  10. Mean Absolute Change and Percentage change From Baseline in a γ-Glutamyl transferase[U/L]

    Time frame: Baseline, Week 36, Week 60

  11. Mean Absolute Change and Percentage change From Baseline in triglyceride [mmol/L]

    Time frame: Baseline, Week 36, Week 60

  12. Mean Absolute Change and Percentage change From Baseline in total cholesterol[mmol/L]

    Time frame: Baseline, Week 36, Week 60

  13. Mean Absolute Change and Percentage change From Baseline in low-density lipoprotein cholesterol[mmol/L]

    Time frame: Baseline, Week 36, Week 60

  14. Mean Absolute Change and Percentage change From Baseline in high-density lipoprotein cholesterol[mmol/L]

    Time frame: Baseline, Week 36, Week 60

  15. Mean Absolute Change and Percent Change from Baseline in Body Weight [kg]

    Time frame: Baseline, Week 36, Week 60

  16. Percentage of Participants who Achieve ≥5%, ≥10% and ≥15% Body Weight Reduction

    Time frame: Baseline, Week 36, Week 60

  17. Mean Absolute Change from Baseline in BMI [kg/m2]

    Time frame: Baseline, Week 36, Week 60

  18. Mean Absolute Change from Baseline in Waist Circumference [cm]

    Time frame: Baseline, Week 36, Week 60

  19. Mean Absolute Change from Baseline in Fasting Plasma Glucose (FPG )[mmol/L

    Time frame: Baseline, Week 36, Week 60

  20. Mean Absolute Change from Baseline in Fasting Blood Insulin[mlU/L]

    Time frame: Baseline, Week 36, Week 60

  21. Mean Absolute Change from Baseline in glycated hemoglobin A1c (HbA1c)[%]

    Time frame: Baseline, Week 36, Week 60

  22. Change from Baseline in Homeostasis Model Assessment IR

    Time frame: Baseline, Week 36, Week 60

  23. Changes from baseline in scores in 36-item Short-Form Health Survey version 2(SF-36v2)

    The SF-36 is a 36 item questionnaire that measures eight multi-item dimensions of health. For each dimension item scores are coded, summed, and transformed on to a scale from 0 (worst possible health state measured by the questionnaire) to 100 (best possible health state)

    Time frame: Baseline, Week 36, Week 60

  24. Change from baseline in scores in NASH-CHECK (patient-reported outcome measure for non-alcoholic steatohepatitis)

    NASH-CHECK scores range from 0 to 10, with higher scores indicating worse symptoms/HRQOL

    Time frame: Baseline, Week 36, Week 60

  25. Change from baseline in scores in PGI-SPatient Global Impression of Severity(PGI-S)

    6-point Patient Global Impression of Severity of NASH symptoms (PGIS; 7-day recall period; responses ranging from "no symptoms" to "very severe").

    Time frame: Baseline, Week 36, Week 60

  26. The proportion of subjects with at least a 25% improvement in liver stiffness measurement (LSM) relative to baseline based on FibroScan and FibroTouch measurements, and the proportion of subjects with at least a 30% improvement in controlled attenuation

    Time frame: Baseline, Week 36, Week 60

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Sep 2026, 15 months.

Of 41 phase 2 interventional studies under Fatty Liver, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 36. This study's 15 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: start Jul 2025 → Jun 2025 and primary completion Apr 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2025
First posted
Apr 22, 2025
StartActual
Jun 20, 2025was Jul 2025
Primary completionActual
Sep 23, 2026was Apr 2026
CompletionEst.
Jul 22, 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 20, 2026
Start date
Jul 1, 2025→Jun 20, 2025
Oct 20, 2026
Primary completion
Apr 30, 2026→Sep 23, 2026 (actual)
Oct 20, 2026
Enrollment
165 (estimated)→181 (actual)
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Recruiting→Active, not recruiting
    Start date Jul 1, 2025→Jun 20, 2025
    Primary completion Apr 30, 2026→Sep 23, 2026 (now actual)
    Enrollment 165 (estimated)→181 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06937749
Responsible party
Sponsor
First posted
Apr 22, 2025
Start date
Jun 20, 2025
Primary completion
Sep 23, 2026
Completion
Jul 22, 2027 (estimated)
Last update
Oct 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mazdutide

Start the discussion